Learn more Semaglutide is a GLP-1 (glucagon-like-peptide-1) receptor agonist and is FDA approved for weight loss
Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, Nslund E, Britton T, et al
In a study of adult survivors of childhood cancer, NR supplementation was not associated with any serious adverse events. Additionally, while not conducted in a cancer-related population, long-term NR supplementation over two years in patients with ataxia telangiectasia reported no adverse effects. While these findings are reassuring and include one of the longer-duration human studies to date, longer-term and broader population studies are still needed
Always consult a healthcare provider before incorporating pharmaceutical or peptide-based interventions into your regimen